Dermatological Manifestations of Glucagon‐Like Peptide‐1 Receptor Agonists [PDF]
JEADV Clinical Practice, EarlyView.ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‑1 RAs) play a pivotal role in treating type 2 diabetes. Despite their widespread use, their dermatological manifestations remain under‐recognized, hence the interest of this systematic review. Objectives This systematic review aims to assess dermatological manifestations associated with
Nour Ghostine, M. Halabi‐Tawil
openalex +2 more sources
Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine
ESC Heart FailureESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi +3 more
doaj +2 more sources
Treatment of type 2 diabetes by free fatty acid receptor agonists [PDF]
, 2014 Dietary free fatty acids (FFAs), such as ω-3 fatty acids, regulate metabolic and anti-inflammatory processes, with many of these effects attributed to FFAs interacting with a family of G protein-coupled receptors.
Hudson, Brian D. +3 more
core +2 more sources
Neural Regeneration Research, 2019 Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 receptor agonists is a breakthrough in the field of neural regeneration research increasing glucagon like peptide-1 bioavailability, hence its neuroprotective activities.
Shaker A Mousa, Bassam M Ayoub
doaj +1 more source
Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study [PDF]
, 2015 AIMS:Glucagon-like peptide 1 receptor agonists (GLP-1 RA) induce weight loss and reduction in adipose tissue, but the effects of GLP-1 RA on the distribution of fat deposits have been poorly investigated. METHODS: In 25 patients with type 2 diabetes (16
Carnevale, Vincenzo +9 more
core +1 more source
Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists [PDF]
, 2014 Patients with type 2 diabetes have a several-fold increased risk of developing cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and stroke are responsible for 75% of all death in patients with diabetes, who present a ...
Andrei C Sposito, Francisco Kerr Saraiva
core +1 more source
Effects of growth factors and receptor blockade on gastrointestinal cancer [PDF]
, 2004 The advent of recombinant peptide technology offers the potential to use one or several peptides to treat a variety of gastrointestinal conditions. However, although cell culture and animal models have shown proof of concept, we are still at a relatively
Ghosh, S, Playford, RJ, Wassan, H
core +2 more sources
Exenatide Improves Bone Quality in a Murine Model of Genetically Inherited Type 2 Diabetes Mellitus [PDF]
, 2017 Type 2 diabetes mellitus (T2DM) is associated with skeletal complications, including an increased risk of fractures. Reduced blood supply and bone strength may contribute to this skeletal fragility.
Andreozzi +64 more
core +6 more sources
Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists [PDF]
Endocrinology and Metabolism, 2021 Glucagon-like peptide-1 (GLP-1) receptor agonists are efficacious glucose-lowering medications with salient benefits for body weight and cardiovascular events. This class of medications is now recommended as the top priority for patients with established
Hun Jee Choe, Young Min Cho
doaj +1 more source
Comment. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes? [PDF]
, 2014 Adam M.
A. M. Deane +6 more
core +1 more source